ClinicalTrials.gg
RecruitingNCT07300696IMPACT-ILDUpdated Dec 24, 2025

Functional MRI for Monitoring Progression and Assessing Trends in ILD

An interventional study of Lung MRI Protocol with Functional and Contrast-Enhanced Sequences in Interstitial Lung Diseases (ILD), sponsored by University Hospital Heidelberg. Recruiting at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by University Hospital Heidelberg · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Lung Diseases, Interstitial with a site in Germany — 18 open to participants now, 26 under way, 13 of them phase 3. Lung Diseases, Interstitial · Germany.

Planned enrollment
25th of 51
200 · median 183
Started
2025
with 3 others
No phase
11 of 66
1 open now
Primary completion
2027-02
later than 5 of 25 live
Registered
61st of 66
by date

Among the 66 studies in Lung Diseases, Interstitial with a site in Germany, this one is the 25th largest by planned enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2025, is one of 11 with no phase, reaches primary completion later than 5 of the 25 other live ones, and was the 61st registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

18 of the 66 studies in Lung Diseases, Interstitial with a site in Germany are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Lung Diseases, Interstitial with a site in Germany, or all of them as a file.
02

Study summary

The main objective of this study is to investigate the utility of functional MRI to differentiate, characterize, and monitor subgroups of ILD. This can be broken down into three specific objectives:

Determine if ILD features observed on high-resolution computed tomography (HRCT), such as ground glass opacities (GGO), are functionally different.

Analyse MRI metrics within each subgroup to determine whether these metrics distinguish different ILDs.

Assess MRI metrics longitudinally to see if these parameters change with disease progression, stability, or reversibility.

03

Conditions studied

  • Interstitial Lung Diseases (ILD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical indication for a routine HRCT because of either newly diagnosed idiopathic pulmonary fibrosis (IPF) or pneumonitis (HP) or idiopathic non-specific interstitial pneumonia (iNSIP), suspected diagnosis, or follow-up
  • Capacity to consent
  • Ability to participate fully in the study (defined by the ability to lie still for the duration of imaging)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy and breast feeding
  • Persons under the age of 18 and persons not able to give
  • Any medical conditions that could hinder the ability to adhere to the protocol
  • Any MRI , including previous allergic reactions to Gd-based MRI contrast material and renal dysfunction ( \< 30 ml min/1,73 m2)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    MRI Examination Protocol

    Diagnostic Test: Lung MRI Protocol with Functional and Contrast-Enhanced Sequences

Interventions

  • Diagnostic testLung MRI Protocol with Functional and Contrast-Enhanced Sequences

    Participants will undergo a lung MRI protocol consisting of structural imaging, non-contrast functional imaging, and contrast-enhanced imaging. Some sequences are custom-developed and performed during free breathing to accommodate patients with respiratory limitations.

06

What researchers measure

Primary outcomes

  1. Identification of ILD Subtypes Using Baseline MRI Metrics

    Assess whether baseline MRI metrics can accurately differentiate subtypes of interstitial lung disease, using clinician diagnosis (based on multidisciplinary discussion) as the reference standard.

    Time frame: Baseline (first MRI scan)

Secondary outcomes

  1. Correlation of Longitudinal MRI Changes with Disease Progression

    Evaluate changes in MRI metrics over time and their correlation with ILD progression, using ATS/ERS/JRS/ALAT criteria.

    Time frame: From enrollment (baseline MRI) through up to 1-year after enrollment; follow-up assessments will only be performed if clinically indicated.

07

Study locations

1 of 2 sites recruiting
  • Thoraxklink Heidelberg - Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany
    Recruiting
  • Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Kiel, 24105, Germany
    Active, not recruiting

    Not enrolling at this site.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.

Of 114 non-industry interventional studies with no phase under Lung Diseases, Interstitial, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 15 months is below that.

Counting every sponsor, half of 119 studies reached it within 27 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 24, 2025
StartActual
Nov 20, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Jul 2027
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07300696
Collaborators
German Center for Lung Research, Thoraxklinik-Heidelberg gGmbH, University Hospital Schleswig-Holstein
Responsible party
Hans-Ulrich Kauczor (Medical Director of Diagnostic and Interventional Radiology at the Heidelberg University Hospital, University Hospital Heidelberg) — Principal investigator
First posted
Dec 24, 2025
Start date
Nov 20, 2025
Primary completion
Feb 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Dec 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion